MENLO PARK, Calif.--(BUSINESS WIRE)--Feb. 22, 2006--Geron Corporation (Nasdaq:GERN) announced today the presentation of studies showing that cardiomyocytes differentiated from human embryonic stem cells (hESCs) survive, engraft and prevent heart failure when transplanted into an infarcted rat heart. The results provide proof-of-concept that transplanted hESC-derived cardiomyocytes show promise as a treatment for myocardial infarction and heart failure.
